pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
354
stories
29d
$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts
biospace
Sep 30, 26
Biopharma needs to reward scientists' judgment
biospace
Sep 30, 26
Biopharma needs to reward scientists' judgment
biospace
Sep 29, 26
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 29, 26
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 28, 26
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
Sep 28, 26
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
Sep 28, 26
Scynexis' BARDA alliance; Bristol Myers' early data for dual-targeting CAR-T
endpoints
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 24, 26
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
Sep 24, 26
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
Sep 23, 26
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
Sep 23, 26
Chinese vaccine scandal leads to life sentence; Flagship wins defense contract
endpoints
Sep 23, 26
Pharmas face off for manufacturing talent amidst reshoring efforts
biospace
Sep 22, 26
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
Sep 22, 26
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
Sep 21, 26
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
Sep 21, 26
FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
endpoints
Sep 21, 26
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
Sep 21, 26
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
Sep 18, 26
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
Sep 18, 26
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
biospace
Sep 18, 26
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
fiercebiotech
Sep 17, 26
Bristol Myers scraps $100M Orum-partnered cancer drug
endpoints
Sep 16, 26
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
biopharma dive
Sep 15, 26
J&J’s Contineum-partnered depression drug flunks another phase 2 test
fiercebiotech
Sep 14, 26
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
← prev
page 4 of 12
next →
